0.64
-0.0174(-2.64%)
Currency In USD
| Previous Close | 0.66 |
| Open | 0.64 |
| Day High | 0.67 |
| Day Low | 0.61 |
| 52-Week High | 4.28 |
| 52-Week Low | 0.31 |
| Volume | 1.16M |
| Average Volume | 3.47M |
| Market Cap | 17.9M |
| PE | -0.35 |
| EPS | -1.85 |
| Moving Average 50 Days | 0.8 |
| Moving Average 200 Days | 1.28 |
| Change | -0.02 |
If you invested $1000 in SeaStar Medical Holding Corporation (ICU) since IPO date, it would be worth $1.02M as of October 07, 2025 at a share price of $0.641. Whereas If you bought $1000 worth of SeaStar Medical Holding Corporation (ICU) shares 3 years ago, it would be worth $2.49 as of October 07, 2025 at a share price of $0.641.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children
GlobeNewswire Inc.
Sep 29, 2025 12:36 PM GMT
Data show results consistent with clinical trial experienceA high level of safety – no device-related adverse eventsStrong survival data extending to 90 days DENVER, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: IC
SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury
GlobeNewswire Inc.
Sep 24, 2025 8:22 PM GMT
Independent DSMB reports zero device-related safety issuesSupports potential clinical benefitTrial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU)
SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children
GlobeNewswire Inc.
Sep 23, 2025 12:23 PM GMT
DENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that preliminary results from the SAVE Surveillance Registry will be presented by SeaStar Medical a